Swiss biotech Roivant Sciences’s business model could be regarded, across the biotech world, as slightly unorthodox. The firm, which focuses on developing drugs through subsidiary companies it develops called ‘vants’, has now built over 20 portfolio companies that have completed nine Phase III trials, eight of which have been successful.
Arguably, its most significant achievement to date has been the launch of its first wholly-owned product: Vtama (tapinarof) cream, 1%,...